Royalty Pharma Plc (RPRX)
NASDAQ · Healthcare · Biotechnology
Royalty Pharma Plc is a Healthcare company with a market capitalization of $32.38B, a trailing P/E ratio of 29.6, and a dividend yield of 1.64%.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 6, 2026 | $0.53 | $0.67 | -20.9% |
| Q4 2025 | February 11, 2026 | $0.38 | $1.50 | -74.7% |
| Q3 2025 | November 5, 2025 | $1.17 | $1.04 | +12.5% |
| Q2 2025 | August 6, 2025 | $1.14 | $1.03 | +10.7% |
| Q1 2025 | May 8, 2025 | $1.06 | $0.95 | +11.6% |
| Q4 2024 | February 11, 2025 | $0.35 | $0.25 | +40.0% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Royalty Pharma Plc's market cap?
As of June 29, 2026, Royalty Pharma Plc (RPRX) has a market capitalization of $32.38B.
What is Royalty Pharma Plc's P/E ratio?
Royalty Pharma Plc trades at a trailing price-to-earnings (P/E) ratio of 29.6. Its forward P/E is 46.5.
Does Royalty Pharma Plc pay a dividend?
Yes — Royalty Pharma Plc pays a dividend yielding 1.64%, an annual payout of $0.90 per share.
What sector is RPRX in?
Royalty Pharma Plc is in the Healthcare sector, specifically the Biotechnology industry.
What was Royalty Pharma Plc's revenue?
In its latest reported fiscal year (ending December 31, 2025), Royalty Pharma Plc reported revenue of $2.38B and net income of $770.95M.
Ask your own questions about RPRX
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.